Tempus AI (TEM) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic vision and platform development

• Built a comprehensive AI-enabled diagnostics and data platform over 10 years, integrating proprietary data and broad distribution to physicians and patients, focused on unlocking precision medicine.

• Platform connects with over 5,000 providers, reaching more than 65% of U.S. academic medical centers and over 55% of oncologists.

• Amassed over 400 petabytes of multimodal healthcare data, including phenotypic, morphologic, and molecular data.

• Data set covers 45 million patients, with 8 million digitized imaging records and 4 million sequenced samples.

• Platform supports diagnostics and data applications, each reinforcing the other through sustainable network effects and a focus on harmonizing data for actionable insights.

Diagnostics business performance and innovation

• Diagnostics business spans genomics and genetics, covering hereditary risk, therapy selection, MRD, and monitoring, integrating best-in-class science and AI-enabled algorithms.

• Acquired Ambry for germline testing, now the largest player in hereditary risk; diagnostics business includes Ambry Genetics and Tempus Genomics with a strong publication and patent portfolio.

• Launched tumor naive and tumor informed MRD products, with ongoing improvements to address market adoption and specificity.

• Delivered approximately 800,000 clinical tests in 2025, achieving 28% growth in Q4; oncology and hereditary businesses both accelerating.

• ASPs expected to rise from $1,630 to $2,200 over several years, driven by FDA approvals, enhanced reimbursement, and migration to higher-value tests.

Data & applications business growth and market position

• Data business generated $316 million in revenue last year, growing at 31%, with net revenue retention at 126%.

• Signed over $2 billion in data licensing agreements, working with 19 of the 20 largest pharma companies and 250+ biotechs.

• $1.1 billion in total contract value (TCV), with $350 million related to 2026, all non-cancelable except for opt-ins, providing strong forward visibility.

• Data is deeply embedded in client environments, making contract renewals highly likely; no significant competition from diagnostic peers due to unique hospital data pipelines and technology investment.

• Applications business distributes algorithmic insights at scale and is expected to become a significant financial catalyst.